Yes, I would like to take this one. One of the things that would be our recommendation on the JODR is to make absolutely sure that we don't repeat the same mistakes we made with CDR. Our point of view is it's not who's at fault in the process; it is who suffers. At the end of the day it is the patient who is denied access. That's the way we have to look upon it. When a patient is denied access, we rob that patient of any new hope that this potentially important medication could bring to the table.
Our point of view is that CDR had asked to expand into oncology products. I think it was the provinces' recommendation to go with the JODR approach. In reality, in principle, both approaches are fine, to say let's have a common denominator of knowledge to make some decisions. The important part, though, is if we look at the end result. The end result is, will CDR or JODR provide access to important medical breakthroughs? For CDR we can say the answer is no. For JODR, we still have to wait and see. I think the focus of us as Canadians has to be on making sure that patients who need access to important, innovative products get that access. That's the job.